Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
| Autor: | David Ames, Christopher C. Rowe, Colin L. Masters, S L Macaulay, Simon M. Laws, Veer Bala Gupta, Victor L. Villemagne, Alan Rembach, Eugene Hone, Stephanie R. Rainey-Smith, Ralph N. Martins, Ashley I. Bush, Madhav Thambisetty, James D. Doecke, Steve Pedrini |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Brain amyloid beta
0301 basic medicine Oncology Pathology medicine.medical_specialty Disease status Early detection Disease lcsh:Geriatrics lcsh:RC346-429 Pathogenesis Plasma 03 medical and health sciences 0302 clinical medicine Hippocampus volume Internal medicine medicine lcsh:Neurology. Diseases of the nervous system Clusterin biology business.industry Blood-Based Biomarkers 3. Good health lcsh:RC952-954.6 Psychiatry and Mental health 030104 developmental biology Apolipoprotein J Potential biomarkers biology.protein Biomarker (medicine) Neurology (clinical) business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 3, Iss 1, Pp 18-26 (2016) Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring |
| ISSN: | 2352-8729 |
| DOI: | 10.1016/j.dadm.2015.12.001 |
| Popis: | Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Methods Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini‐mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B‐positron emission tomography), and total adjusted hippocampus volume. Results ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text